Vesilute

What is Vesilute?

Vesilute is a synthetic dipeptide consisting of glutamic acid and aspartic acid (Glu-Asp), developed as part of Vladimir Khavinson's bioregulator peptide system. It is classified as a Cytogen — a lab-synthesized short peptide designed to mirror the regulatory effects of peptides naturally found in bladder tissue. Its natural-extract counterpart is Chitomur. Khavinson's bioregulator research spans over 40 years, with short peptides like Vesilute proposed to interact directly with DNA to modulate gene expression in target tissues.

What Vesilute Is Investigated For

Vesilute is investigated for age-related bladder dysfunction, overactive bladder, nocturia, and prostate-adjacent urinary symptoms within the Khavinson bioregulator framework, with the proposed mechanism being direct DNA binding and epigenetic reactivation of bladder-tissue genes by the Glu-Asp dipeptide. The evidence base is genuinely thin, and part of it points the wrong way. The Glu-Asp (ED) dipeptide has been tested directly a few times, but never in bladder tissue: a 2019 Nucleic Acids Research study from Khavinson's own group found ED had no binding sites on double-stranded DNA in docking and ranked last of four dipeptides in a laboratory gel-shift binding test (PMID 31598715), a 1999 mouse and cell study found Glu-Asp no more immunologically active than its two constituent amino acids (PMID 10606007), and a 2023 computer-modeling study predicted that ED binds the LAT1, LAT2, and PEPT1 transporters well (PMID 36979488). The clinical data cited for Vesilute actually come from Chitomur — the natural-extract bladder-tissue Cytomax counterpart — in two small 2013 Russian studies: a randomized, blinded study in women aged 48–80 with overactive bladder, and a randomized, placebo-controlled study in men aged 62–83 with BPH. Neither abstract reports sample sizes or effect sizes. Inferring an effect from Chitomur to the isolated synthetic dipeptide is a leap the originating literature does not defend. The honest caveats are severe: no Vesilute-specific clinical trials in any urologic indication, no human pharmacokinetic data, a proposed DNA-binding mechanism that the originating group's own experiment did not support, and no Western clinician operating a Vesilute protocol for any condition. Standard BPH and overactive bladder care (alpha-blockers, 5-alpha-reductase inhibitors, anticholinergics, beta-3 agonists) is dramatically better evidenced, and Vesilute should not delay appropriate urologic evaluation.

History & Discovery

Vesilute is the synthetic Cytogen counterpart to Chitomur, a bladder-tissue peptide complex (Cytomax) developed within Vladimir Khavinson's bioregulator program at the St. Petersburg Institute of Bioregulation and Gerontology. It is one of the simplest sequences in the entire bioregulator catalog — a dipeptide of just glutamic acid and aspartic acid (Glu-Asp) — and is positioned as the chemically defined active fragment representing bladder-tissue regulation. Vesilute is honestly one of the most thinly characterized peptides on this site. The Glu-Asp dipeptide has barely been studied in its own right, and never in bladder tissue: a 1999 immunology study found it no more active than its constituent amino acids, and a 2019 Khavinson-group DNA-binding study found it one of the weakest DNA binders tested. The closest direct human evidence is for Chitomur (the natural-extract counterpart) in small 2013 Russian studies of overactive bladder and benign prostatic hyperplasia. Independent Western characterization of the ED dipeptide is absent, and the claim that a two-amino-acid peptide reliably penetrates cell nuclei to bind ATTT motifs in bladder-specific gene promoters is among the more aggressive epigenetic claims in the bioregulator literature — one the originating group's own experiment did not support. Honest assessment: this is among the lowest-evidence peptides in the Khavinson lineup, and the marketing language around it routinely outruns the underlying data.

How It Works

Vesilute is a tiny two-amino-acid peptide proposed to enter cells and reach the nucleus, where it may interact with DNA to reactivate genes involved in bladder tissue maintenance. As we age, some of these genes become silenced — Vesilute is thought to help reverse that process in bladder and urinary tract tissue.

Vesilute (Glu-Asp) is proposed to bypass cell-surface receptors due to its small molecular size, penetrating both cytoplasmic and nuclear membranes to interact directly with DNA and histone proteins. Khavinson-program materials describe it binding AT-rich DNA sequences (particularly ATTT motifs) in regulatory regions of bladder-related genes, promoting chromatin decondensation and reactivating age-silenced gene expression, and inhibiting glycogen aggregation in bladder smooth muscle; we found no indexed paper demonstrating either claim for ED. The one direct experimental test cuts against the DNA claim: in a 2019 Nucleic Acids Research study from the same group, ED had no binding sites on double-stranded DNA in docking and the weakest gel-shift binding of four dipeptides tested (PMID 31598715). A 2023 docking study predicted ED is a good ligand for the LAT1, LAT2, and PEPT1 transporters (PMID 36979488), which would allow cell entry, and a 1999 study found Glu-Asp no more immunologically active than glutamate and aspartate on their own (PMID 10606007). Broader Khavinson work proposing nuclear penetration by short peptides rests largely on docking studies (e.g. PMID 27909961), and the tissue-specificity mechanism for Vesilute remains uncharacterized.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Vesilute:

• 01Bladder-specific studies — no indexed study tests the Glu-Asp dipeptide in bladder cells, urothelium, detrusor muscle, or any urologic model; the few ED studies that exist are DNA-binding, transporter-docking, and immunology work.
• 02The DNA-binding mechanism itself — the claim that ED targets ATTT motifs in bladder-cell gene promoters is unconfirmed, and the originating group's own 2019 experiment found ED among the weakest DNA binders tested (PMID 31598715).
• 03Primary Chitomur data — the two 2013 Chitomur studies' abstracts report no sample sizes or effect sizes, so the figures circulating online for them cannot be verified from indexed sources.
• 04Human pharmacokinetics — oral, sublingual, and parenteral bioavailability of Glu-Asp is uncharacterized.
• 05Blinded randomized controlled trials in overactive bladder, nocturia, or BPH — there are no Vesilute-specific RCTs in any defined urologic indication.
• 06Tissue-specificity mechanism — why Glu-Asp should target bladder smooth muscle or urothelium rather than other tissue types lacks any direct experimental validation.
• 07Long-term safety — no chronic-dosing data exists in any species at any dose.

Forms & Administration

Vesilute is available in capsule, sublingual, and injectable formats. Capsule protocols typically involve 2 capsules daily for 10-30 days. Injectable research-chemical forms, where used, follow the general bioregulator convention of roughly 100–200 mcg per subcutaneous dose (see Dosing); no validated injectable dose exists. All peptides should only be used under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Vesilute is not FDA-approved for any indication. Bladder, urinary, and prostate claims significantly exceed what controlled clinical evidence — which for the Glu-Asp dipeptide specifically is essentially nonexistent — would support. It should not substitute for evaluation of overactive bladder, BPH, or any urologic condition by a qualified clinician.

Timeline of Effects

Common Questions

Who Vesilute Is NOT For

Drug & Supplement Interactions

There are no documented clinical drug interactions for Vesilute because there are no human pharmacovigilance studies and no peptide-specific pharmacokinetic data. What follows is theoretical. The most plausible practical concern is with established overactive-bladder pharmacotherapy (anticholinergics like oxybutynin and solifenacin, beta-3 agonists like mirabegron) and with BPH pharmacotherapy (alpha-blockers like tamsulosin, 5-alpha-reductase inhibitors like finasteride). Layering an unstudied bladder-targeted bioregulator onto these agents has not been characterized for additive or opposing effects, and a false sense of efficacy from Vesilute could discourage appropriate dose titration of evidence-based agents. Concurrent use during genitourinary chemotherapy is mechanistically discouraged on the same logic that applies to other bioregulators with proliferation-related claims. Patients on any urologic medication should disclose Vesilute use to their prescribing clinician.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions